Medical device manufacturer ivWatch has announced that its FDA-cleared standalone device has been made compatible with Philips IntelliVue Patient Monitors.
The interoperability will enable the integration of the ivWatch Model 400 with Philips IntelliVue Patient Monitors to receive in-room and remote notifications and electronic medical record (EMR) data capture.
Go deeper with GlobalData
ivWatch president and CEO Gary Warren said: “Interoperability with an industry leader like Philips enables IV infiltration alerts and IV assessment data to be more widely available to health care providers.”
The ivWatch Model 400 can be integrated with any infusion pump or IV gravity infusion to receive infiltration notifications through the Philips IntelliBridge EC10 Interface Module or IntelliBridge EC10 integral Interface Board equipped with Open Interface Driver (ED101) and EC5 ID Module on MP40-90 and MX400-800 Philips patient monitors.
The visual notifications will facilitate response times by alerting clinicians of infiltration events and mitigate associated risks.
These notifications can be generated in in-room designated Philips patient monitor and also at the remote nursing station monitors.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataFurthermore, a clinician will be able to document the overall condition of the IV or identify any infiltration caused through the Model 400 user interface while diagnosing patients.
This compatibility with Philips systems is also expected to enable healthcare facilities to procure the IV assessment data in their existing EMR systems.
Warren added: “Our vision is to eliminate harm associated with IV infiltrations and extravasations.
“We will continue to work with like-minded companies to make this technology solution available to as many healthcare organizations as possible as we embark on a new IV therapy standard of care.”
